AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03272737 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1RM Test
Description: The dynamic force of the lower limb muscles will be evaluated by the maximal repetition of knee extension and leg press exercise, according to the protocol presented in a previous study \[37\]. The elderly will perform a warm up consisting of 1 series with 10 unloaded repetitions. After the warm up, the mass to be lifted will be progressively increased until the maximum load that can be lifted is reached, with a maximum limit of 5 attempts and a 3 to 5 minutes interval between them. The test will be conducted by a physical education professional who will verbally encourage participants throughout these steps and perform the load adjustment at week 5 and 10 (Radaelli, 2014).
Study NCT03272737 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Speed gait test
Description: To measure the gait speed of participants they will walk 4.6 metres and the time needed to cover this distance is measured. The mean of three attempts is recorded and divided by the distance. The participants included must achieve in the walking test an average of \< 0.,9 m/s (Guralnik, 1994).
Study NCT03272737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venous occlusion plethysmography protocol
Description: A mercury-filled silastic tube, connected to a low-pressure transducer and a plethysmograph (D.E. Hokanson), will be placed around the largest circumference of the calf region. One cuff will be placed around the ankle and another around the thigh. The ankle cuff will be inflated to a supra-systolic pressure 30 seconds before starting the measurements. At 15-second intervals, the cuff around the thigh will be inflated above the venous pressure for a period of seven to eight seconds. Increased tension in the silastic tube reflects an increase in leg volume and vasodilation. The signal of the muscle blood flow wave will be recorded on a polygraph and analysed every minute, averaging three records per minute. The protocol will be performed during 5 minutes of rest, 3 minutes isometric exercise and 2 minutes of recovery (Bahia, 2006).
Study NCT03272737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of Arterial Stiffness - Pulse Wave Analysis and Velocity
Description: Arterial stiffness will be estimated from the carotid-femoral aortic pulse wave velocity \[33\]. Carotid-femoral aortic pulse waves will be recorded by tonometry (SphygmoCor, AtCor Medical, Australia). At the same time, an electrocardiogram will be obtained to calculate the wave transit time. Two distances will be measured: the recording point of the carotid artery and the sternal furcula (distance 1) and the sternal furcula and the recording point in the femoral artery (distance 2). The distance travelled by the pulse wave will be calculated as distance 2 - distance 1. The carotid-femoral aortic pulse wave velocity will be calculated as: carotid-femoral aortic pulse wave velocity = ¼ \* distance travelled by the pulse wave (m) / transit time(s).
Study NCT03272737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Isometric handgrip exercise protocol
Description: In a supine position, the maximal voluntary handgrip force will be determined as the highest force in 3 consecutive attempts using a Jamar hydraulic palmar dynamometer (Asimow Engineering, CAL, USA). For activation of the central command, mechanoreceptors and muscular metaboreceptors the individual will perform, after 5 minutes of rest (baseline records), 3 minutes of exercise at 30% MVC. This manoeuvre isolates the activation of muscle metaboreceptors, observing the selective activation of these. After the isometric handgrip exercise, 2 minutes of recovery will be performed. Throughout the protocol muscle blood flow, blood pressure and heart rate will be recorded.
Study NCT03272737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vasodilatory capacity
Description: The vasodilatory capacity will be calculated as the percentage of increase of the diameter of the brachial artery and femoral post occlusion in relation to its basal values.
Study NCT03272737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Basal blood flow and vasodilatory capacity - Flow mediated dilation (FMD)
Description: Images of the brachial artery will be recorded by a two-dimensional ultrasonography device with a spectral Doppler and linear transducer (Ultra-0122, Philips, The Netherlands).
Study NCT03272737 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life EuroQol-5 Domain
Description: This questionnaire is used to estimate the quality of life in participants before and after the study.
Study NCT03272737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anthropometric Assessment
Description: Anthropometric measurements will be made before and after the training program following the standardization of the International Society for Anthropometric Assessments. The body mass will be measured with an accuracy of 0.1 kg (Filizola). The stature will be obtained by means of the stadiometer with an accuracy of 0.5 cm. The BMI will be calculated as body mass divided by height squared. The circumference of the quadriceps will be measured with a tape measure (Seca) with a precision of 0.1 cm.
Study NCT02806843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehab InterCap system and 3D Kinect
Description: The therapist will conduct a therapy session which will consist of various activities of daily living. During the session, the motion of the therapist and patients will be collected with a custom motion capture system (Rehab InterCap) and 3D visual mapping may take place using the Kinect device, audio will be recorded, and basic measurements of length (i.e. the distance from a participant's shoulder to elbow) will be taken. Patients and therapists will wear the sensors to capture their arm movements. 3D video motion capture may be completed with some subjects. This will involve subjects wearing reflective markers on their upper arms in addition to the intercap sensors.
Study NCT01907698 — intervention group
Intervention type: BEHAVIORAL
Intervention: Vaginal intercourse
Description: vaginal intercourse at least twice a week
Study NCT01980004 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium Citrate Supplementation
Description: 20 mEq taken twice daily
Study NCT01980004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Education
Description: Dietary counseling will include both a verbal discussion in the clinic regarding increased fluid intake, a moderate calcium rich diet and lemonade therapy as well as receiving a written handout on these topics.
Study NCT01502592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: OncCore Biopsy (+ Cryo) Date\*~* Pre- and post- cryo MRI~* Core biopsy x ≥3~* Cryoablation Optional pre-surgery MRI day prior or day of Mastectomy Date\* Safety assessment 30 (+/-10) days after surgery research bloods 30 (+/-10) days after surgery.\*
Study NCT01502592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab Appt. with Med Onc Ipilimumab administered Core Biopsy Date\*~* MRI~* Core biopsy x ≥3 Optional pre-surgery MRI biopsy prior or day of Mastectomy Date\* Safety assessment 2-3 weeks post-mastectomy (co-ordinated with off-study surgery follow-up appt if feasible) and then every 2-3 weeks thereafter until at least 12 weeks post ipilimumab date. # Research bloods 30 (+/-10) days after surgery.
Study NCT01059305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
Study NCT03783676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Receive remifentanil bolus and infusion guided by an algorithm.
Study NCT01888653 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Bias Modification (ABM)
Description: The training protocol consisted of 160 trials per session with 120 angry-neutral and 40 neutral-neutral trials. Each participant was trained with an alternative set of faces to the one used in the assessment task (i.e. if measured with set A then trained with set B and vice-versa). In the ABM condition, training was contin- gent on the bias measured at pre-treatment. Specifically, for those showing a bias toward the threat, the target appeared at the neutral-face location in 100% of the threat-neutral trials, while for those showing a bias away from the threat, the target appeared at the threat-face location in 100% of the threat-neutral trials.
Study NCT01888653 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention control training (ACT)
Description: In the ACT condition, threat- face location, probe location, and probe type were fully counter- balanced with no contingency between face valence and probe location, thus resembling the assessment task.
Study NCT03165084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention arm: Person-centred interactive self-management support
Description: Person-centred tailored digital self-management support hypothesised to decrease HbA1c, improve other metabolic measurements, improve lifestyle habits, and increase diabetes empowerment, increase diabetes-dependent quality of life, improve illness perception, and improve eHealth literacy.~Access to the diabetes mobile application and the homepage during 16 weeks. Each individual will set personal goals for use of the digital resources.
Study NCT03165084 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control arm
Description: Participants will receive usual care and take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
Study NCT03783676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Receive normal saline bolus and infusion guided by the remifentanil algorithm.
Study NCT01251406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous administration for 8 hours a day for 10 days
Study NCT01251406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNRG-1 Dose 1
Description: Daily subcutaneous administration for 8 hours a day for 10 days
Study NCT01251406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNRG-1 Dose 2
Description: Daily subcutaneous administration for 8 hours a day for 10 days
Study NCT00535379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Patients will receive SUTENT 37.5mg (3 x 12.5mg capsules) PO daily in the morning after breakfast. After 2 weeks without treatment-related adverse events grade ≥ 2 (ECOG common toxicity criteria: refer to Protocol Attachment A.4) a SUTENT dose escalation to 50mg (4 x 12.5mg capsules) PO daily has to be performed. Treatment will continue until patients develop progression of disease or until unacceptable adverse events occur.
Study NCT04625010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swaddling
Description: Swaddling is a wrapping procedure in which a baby's arms and legs are comfortable, sometimes only the arms are wrapped inside, and two ends of fabric are crossed on the chest of the baby, generally with thin cotton and soft fabric or a blanket. In the swaddling group, neonates were placed in the supine position on a blanket. In compliance with the newborn anatomic posture, the legs were wrapped in the flexion and abduction position. The arms of the neonates were placed close to their torso with both hands, without restraining limb movements. Swaddling was carried out 1 minute before the heel stich procedure and continued 3 minutes after the procedure. The neonate remained on the examination table during the swaddling procedure. Swaddling was applied not too loose or too tight during the procedure.
Study NCT04625010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal holding
Description: Neonates in this group were held in their mothers' lap while their mothers were seated reclining on a comfortable chair. Neonates remained clothed in their mothers' lap during the heel stick procedure, and no breastfeeding was administered during the procedure. Holding was continued for a minimum of 3 minutes during and after the procedure.
Study NCT03165084 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: External comparison group
Description: External comparison groups in order to analyse possible Hawthorne effects.
Study NCT03873454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sennheiser non-occlusive headphones
Description: Patients listened to music of their choice using non-occlusive headphones
Study NCT03873454 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sennheiser non-occlusive headphones without music
Description: Patients wore non-occlusive headphones but had no music playing
Study NCT03873454 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Sennheiser non-occlusive headphones
Description: Patients did not wear non-occlusive headphones and did not listen to music
Study NCT04530578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin sodium
Description: Nebulized Heparin every 8 hours plus Subcutaneous Enoxaparin every 24hours
Study NCT04530578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Subcutaneous Enoxaparine every 24 hours
Study NCT04530578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Subcutaneous Enoxaparine every 24 hours
Study NCT04910633 — intervention group
Intervention type: OTHER
Intervention: COCA is an observational study based on retrospective data issued from patient medial file.
Description: The following parameters will be collected from the medical files of the patients involved in this study:~* Age~* Gender~* Cancer type~* Cancer Stage~* Cancer Treatment~* COVID-19 severity (based on chest X-Ray damage. Low ≤25%, Middle: between 25-50%, High above 50%)~* Living Status~* Attribution of Mortality to COVID status~* Comorbidities
Study NCT00950482 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TA
Description: In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
Study NCT00950482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AA
Description: In Alternative acupuncture (AA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
Study NCT00950482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WC
Description: Waiting Group
Study NCT03723226 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Load Resistance Exercise
Description: Subjects allocated to Low Load Resistance Exercise will undergo 6 weeks of single-legged low load (25%) resistance exercise. Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
Study NCT03723226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Load Resistance Exercise + BFR
Description: Subjects allocated to Low Load Resistance Exercise + BFR will undergo 6 weeks of single-legged low load (25%) resistance exercise with blood flow restriction (60% occlusion pressure). Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
Study NCT05585645 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stimus (NNG-DEPO)
Description: Nanogen's Darbepoetin alfa 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe
Study NCT05585645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stimus (NNG-DEPO)
Description: Nanogen's Darbepoetin alfa 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe
Study NCT01798342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Maltodextrin
Description: The volunteers underwent MRI after the ingestion of the dietary supplement in a crossover fashion aiming at measuring the gastric residual volume
Study NCT01798342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of GLN before MRI
Study NCT04530604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: All patients will receive 25 milligram/kilogram/day (mg/kg/day) of defibrotide, given in 4 divided doses (approximately every 6 hours), each dose infused over 2-hours intravenously (IV).~The planned duration of study therapy is 7 days (while in the hospital), with the following qualifications:~* Patients who respond to study therapy prior to day 7 (able to discontinue oxygen) will discontinue study therapy at that earlier time point.~* Patients who have not responded to study therapy by day 7 of therapy, evidenced by \<20% reduction (or a worsening) of the amount of supplemental oxygen they are receiving, will discontinue study therapy at day 7.~* Patients who have evidence of a partial pulmonary response by day 7 (>20% reduction in supplemental oxygen requirement, but still require supplemental oxygen) may elect to continue to receive study drug through an additional 7 days of study (total 14-day therapy course).
Study NCT02209103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lozenge containing citrus flavonoid
Study NCT02209103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lozenge containing citrus flavonoid formulation
Study NCT02209103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Identical looking placebo
Study NCT00118612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tree MATA MPL - Therapeutic Regimen
Description: 600, 1600, 4000, 4000 SU/0.5 mL
Study NCT00118612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tree MATA MPL - Intermediate dose
Description: 300, 600, 1600, 1600 SU/0.5 mL
Study NCT00118612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tree MATA MPL - Low dose
Description: 300, 300, 300, 300 SU/0.5 mL
Study NCT00118612 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: L-tyrosine 2% w/v , 4 injections
Study NCT01721954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX6m
Study NCT01721954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX6m
Study NCT01721954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres microspheres
Study NCT02840864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonography assisted breast surgery
Study NCT02840864 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonography assisted breast surgery
Study NCT00867971 — intervention group
Intervention type: OTHER
Intervention: Measuring intraoccular pressure
Description: Measurement of intraoccular pressure by tonometry
Study NCT03353597 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Transfusion
Description: All subjects will receive monthly, 2-unit transfusions of young healthy male donor plasma for total of 6 treatments. The plasma will be administered at a transfusion services facility in a manner consistent with generally accepted and standard guidelines for plasma transfusions.
Study NCT06297044 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological assessment
Description: * APACS assessing various aspects of pragmatic communication abilities;~* SET assessing cognitive and emotional theory of mind;~* COAST assessing functional communication impairments in daily activities and their impact on the quality of life after the illness onset;~* PWB assessing the individual's perceived quality of life and psychological well-being;~* other neuropsychological assessment tools depending on the participant's pathology and routinely used in the clinical practice within the Institution.
Study NCT01508390 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife Boost
Description: 21 Gy in 7 Gy per day, 3 fractions, Every other day
Study NCT03321409 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The general population
Description: After recruiting participants, collecting the baseline data, the SSS-CN and PHQ-15 will be carried out. Then validating the reliability, validity of the SSS-CN will be compared with the PHQ-15.
Study NCT03321409 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Patients with suspected CAD
Description: In patients with suspected CAD, after recruiting participants, collecting the baseline data, the SSS-CN and PHQ-15 will be carried out before undergo coronary angiography. Then the prevalence of somatic symptoms will be investigated.
Study NCT03671785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRIM-DJ2727
Description: Twice filtered fecal microbiota product from three screened healthy donors will be lyophilized and encapsulated in enteric-coated capsules. Each dose of enteric coated capsules consists of 60 grams of stool and will be administered orally twice-weekly for 12 consecutive weeks
Study NCT03671785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria. The placebo will consist of Lactose (spray-dried United States Pharmacopeia (USP) 64.385gm), food color, powdered Black, Brown, and Yellow in the enteric capsules. Placebo will be administered orally twice-weekly for 12 consecutive weeks